[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
September 22/29, 2015

FDA Expanded Access Programs for Experimental Medicines—Reply

Author Affiliations
  • 1Merck, Kenilworth, New Jersey
  • 2formerly with Merck
JAMA. 2015;314(12):1296. doi:10.1001/jama.2015.9728

In Reply We agree with Dr Nightingale that equal access to information is essential for fairness in expanded access or other compassionate use programs.

Nightingale suggests several possible mechanisms for increasing patient access to information. We look forward to working with others to consider their ramifications and means for effective and efficient implementation.